Literature DB >> 12660284

Macroprolactinaemia associated with prolactin adenoma.

Chantal Mounier1, Jacqueline Trouillas, Bruno Claustrat, Robert Duthel, Bruno Estour.   

Abstract

BACKGROUND: Macroprolactinaemia, defined as hyperprolactinaemia with a predominance of, or only, the big big prolactin (bbPRL) isoform, is considered idiopathic and poorly symptomatic. Since its association with a PRL adenoma is poorly documented, we examined a series of 13 patients with tumoral hyperprolactinaemia for the presence of macroprolactinaemia.
METHODS: From a series of 36 patients with hyperprolactinaemia studied for PRL isoforms, we selected 13 with hyperprolactinaemia and a prolactinoma, and divided them into two groups on the basis of the predominant PRL isoform, the large PRL group (five patients), with a predominance of the big big PRL isoform, and the monomeric PRL (mPRL) group (eight patients), with a predominance of the mPRL isoform. Plasma PRL concentrations were measured by radioimmunoassay, while plasma PRL heterogeneity was studied by gel filtration chromatography. The plasma autoantibody-bound PRL and the histology of the tumours were also studied.
RESULTS: Macroprolactinaemia was seen in five out of the 13 patients with a PRL adenoma. The clinical and biological characteristics of the groups with and without macroprolactinaemia were similar. In the large PRL group, no evidence for anti-PRL autoantibodies was found and the prolactinomas were either typical or exhibited unusual aggregates of immunoreactive PRL deposits, the latter suggesting the tumoral origin of these large forms.
CONCLUSION: Our results suggest that PRL adenoma may be associated with macroprolactinaemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660284     DOI: 10.1093/humrep/deg172

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

2.  Macroprolactinemia, like hyperprolactinemia, may promote platelet activation.

Authors:  Inan Anaforoglu; Melek Eda Ertorer; Ilknur Kozanoglu; Birsel Unal; Filiz Eksi Haydardedeoglu; Okan Bakiner; Emre Bozkirli; Neslihan Bascil Tutuncu; Nilgun Guvener Demirag
Journal:  Endocrine       Date:  2010-02-03       Impact factor: 3.633

3.  Identification of IgG-immunocomplex macroprolactin with an immunometric "sandwich" system: technical and clinical considerations.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; A Valentini
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

4.  Macroprolactinemia and Empty Sella Syndrome.

Authors:  Ach Taieb; Kacem Njah Maha; Yosra Hasni El Abed; Amel Maaroufi Beizig; Molka Chaieb Chadli; Koussay Ach
Journal:  Pan Afr Med J       Date:  2017-08-14

5.  Macroprolactinemia in a patient with invasive macroprolactinoma: a case report and minireview.

Authors:  Atanaska Elenkova; Zdravka Abadzhieva; Nikolai Genov; Vladimir Vasilev; Georgi Kirilov; Sabina Zacharieva
Journal:  Case Rep Endocrinol       Date:  2013-01-15

6.  Gigantomastia and Macroprolactinemia Responding to Cabergoline Treatment: A Case Report and Minireview of the Literature.

Authors:  Fatma Dilek Dellal; Didem Ozdemir; Cevdet Aydin; Gulfem Kaya; Reyhan Ersoy; Bekir Cakir
Journal:  Case Rep Endocrinol       Date:  2016-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.